---
title: "Azora Therapeutics surges 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304147418.md"
description: "Azora Therapeutics rose 8.23% to US$4.210. Up 170.97% over six months and down 23.64% from IPO price."
datetime: "2026-11-03T16:55:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304147418.md)
  - [en](https://longbridge.com/en/news/304147418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304147418.md)
generator: "portal-rs"
---

# Azora Therapeutics surges 8%

Azora Therapeutics (AZR.US) surged more than **8%** during regular trading to **$4.21**.

The stock is up 13.21% over the past five sessions, up 170.97% over the past six months and down 23.64% from its IPO price. It sits 221.37% above its 52-week low of US$1.310. The intraday swing reached 10.03%.

The Nasdaq Composite is down 4.13% over the past five sessions and up 9.21% year to date.

Matt Davidson has been appointed president and chief executive officer. The company's lead candidate AT177 for ulcerative colitis is expected to enter a Phase 1 clinical trial in the first half of 2027, and existing cash reserves are projected to fund operations into 2028.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [AZR.US](https://longbridge.com/en/quote/AZR.US.md)

## Related News & Research

- [Adial Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Vassiliki Economides](https://longbridge.com/en/news/303813186.md)
- [Is ServiceNow (NOW) Trading At Too High A Premium For Earnings?](https://longbridge.com/en/news/306039339.md)
- [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md)
- [How did Coinbase stop deepfake Elon Musk’s promise to double your crypto?](https://longbridge.com/en/news/306049317.md)
- [Lenovo Group: Record sales and adjusted profit growth were offset in reported results by warrant revaluation losses](https://longbridge.com/en/news/306059225.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**